Latest Insider Transactions at Clearside Biomedical, Inc. (CLSD)
This section provides a real-time view of insider transactions for Clearside Biomedical, Inc. (CLSD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Clearside Biomedical, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Clearside Biomedical, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 01
2024
|
Ngai Hang Victor Chong Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
36,500
+26.74%
|
$36,500
$1.0 P/Share
|
|
Jun 24
2024
|
Ngai Hang Victor Chong Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
23,500
+27.01%
|
$23,500
$1.06 P/Share
|
|
May 15
2024
|
Benjamin R Yerxa |
BUY
Open market or private purchase
|
Direct |
7,813
+30.32%
|
$7,813
$1.31 P/Share
|
|
Apr 18
2024
|
Anthony S Gibney |
BUY
Open market or private purchase
|
Direct |
93,290
+48.26%
|
$93,290
$1.3 P/Share
|
|
Apr 17
2024
|
Anthony S Gibney |
BUY
Open market or private purchase
|
Direct |
6,710
+50.0%
|
$6,710
$1.25 P/Share
|
|
Mar 20
2024
|
Ngai Hang Victor Chong Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+50.0%
|
$30,000
$1.6 P/Share
|
|
Feb 07
2024
|
Bradford T Whitmore > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
444,444
+9.0%
|
$444,444
$1.35 P/Share
|
|
Jan 19
2024
|
Charles A. Deignan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,900
-3.24%
|
$12,900
$1.28 P/Share
|
|
Jan 19
2024
|
George M Lasezkay CEO |
SELL
Open market or private sale
|
Direct |
18,000
-3.71%
|
$18,000
$1.27 P/Share
|
|
Nov 01
2023
|
Bradford T Whitmore > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
64,366
+1.56%
|
$0
$0.74 P/Share
|
|
Oct 31
2023
|
Bradford T Whitmore > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
70,812
+1.75%
|
$0
$0.73 P/Share
|
|
Oct 30
2023
|
Bradford T Whitmore > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
600
+0.02%
|
$0
$0.68 P/Share
|
|
Oct 03
2023
|
Nancy J Hutson |
BUY
Open market or private purchase
|
Direct |
10,000
+9.71%
|
$0
$0.86 P/Share
|
|
Sep 25
2023
|
Clay Thorp |
BUY
Open market or private purchase
|
Direct |
10,000
+19.79%
|
$0
$0.86 P/Share
|
|
Sep 22
2023
|
William D. Humphries |
BUY
Exercise of conversion of derivative security
|
Direct |
22,727
+30.81%
|
$0
$0.4 P/Share
|
|
Sep 13
2023
|
Charles A. Deignan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,090
+7.9%
|
$0
$0.4 P/Share
|
|
Jan 20
2023
|
Thomas Ciulla Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,700
-4.48%
|
$13,700
$1.47 P/Share
|
|
Jan 19
2023
|
George M Lasezkay CEO |
SELL
Open market or private sale
|
Direct |
20,030
-3.97%
|
$20,030
$1.46 P/Share
|
|
Jan 19
2023
|
Charles A. Deignan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,030
-3.72%
|
$14,030
$1.5 P/Share
|
|
Jan 10
2023
|
Thomas Ciulla Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,170
-0.71%
|
$2,170
$1.62 P/Share
|
|
Dec 31
2022
|
Thomas Ciulla Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+1.6%
|
$0
$0.95 P/Share
|
|
Dec 21
2022
|
Clay Thorp |
BUY
Open market or private purchase
|
Direct |
14,000
+31.45%
|
$14,000
$1.02 P/Share
|
|
Dec 20
2022
|
Charles A. Deignan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,636
+5.89%
|
$0
$0.4 P/Share
|
|
Dec 15
2022
|
Clay Thorp |
BUY
Other acquisition or disposition
|
Direct |
8,522
+34.03%
|
-
|
|
Dec 15
2022
|
Clay Thorp |
SELL
Other acquisition or disposition
|
Indirect |
1,406,507
-28.41%
|
-
|
|
Nov 17
2022
|
Nancy J Hutson |
BUY
Open market or private purchase
|
Direct |
30,000
+26.55%
|
$30,000
$1.33 P/Share
|
|
Jun 30
2022
|
Thomas Ciulla Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+1.62%
|
$5,000
$1.25 P/Share
|
|
Jan 19
2022
|
George M Lasezkay CEO |
SELL
Open market or private sale
|
Direct |
10,800
-2.1%
|
$21,600
$2.12 P/Share
|
|
Jan 19
2022
|
Thomas Ciulla Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,050
-2.97%
|
$18,100
$2.13 P/Share
|
|
Jan 19
2022
|
Charles A. Deignan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,833
-2.45%
|
$17,666
$2.09 P/Share
|
|
Jan 18
2022
|
George M Lasezkay CEO |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+15.91%
|
-
|
|
Jan 18
2022
|
Thomas Ciulla Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+12.75%
|
-
|
|
Jan 18
2022
|
Charles A. Deignan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+10.83%
|
-
|
|
Jan 11
2022
|
George M Lasezkay CEO |
SELL
Open market or private sale
|
Direct |
5,100
-1.21%
|
$10,200
$2.46 P/Share
|
|
Jan 10
2022
|
William D. Humphries |
BUY
Exercise of conversion of derivative security
|
Direct |
22,727
+44.53%
|
$0
$0.15 P/Share
|
|
Oct 29
2021
|
Nancy J Hutson |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+30.87%
|
$80,000
$2.05 P/Share
|
|
Sep 21
2021
|
Charles A. Deignan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,800
-0.88%
|
$16,800
$6.41 P/Share
|
|
Sep 21
2021
|
George M Lasezkay CEO |
SELL
Open market or private sale
|
Direct |
3,525
-0.83%
|
$21,150
$6.46 P/Share
|
|
Sep 21
2021
|
Thomas Ciulla Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,560
-0.99%
|
$15,360
$6.4 P/Share
|
|
Sep 01
2021
|
Bradford T Whitmore > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
213,203
-8.11%
|
$1,279,218
$6.89 P/Share
|
|
Aug 31
2021
|
Bradford T Whitmore > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
107,682
-3.94%
|
$646,092
$6.96 P/Share
|
|
Aug 30
2021
|
Bradford T Whitmore > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
99,400
-3.51%
|
$695,800
$7.06 P/Share
|
|
Aug 16
2021
|
Nancy J Hutson |
BUY
Open market or private purchase
|
Direct |
3,000
+18.75%
|
$15,000
$5.68 P/Share
|
|
Jun 21
2021
|
Charles A. Deignan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,938
-0.91%
|
$11,752
$4.37 P/Share
|
|
Jun 21
2021
|
George M Lasezkay CEO |
SELL
Open market or private sale
|
Direct |
3,707
-0.86%
|
$14,828
$4.38 P/Share
|
|
Mar 19
2021
|
George M Lasezkay CEO |
SELL
Open market or private sale
|
Direct |
3,370
-0.78%
|
$6,740
$2.82 P/Share
|
|
Mar 12
2021
|
Nancy J Hutson |
BUY
Open market or private purchase
|
Direct |
5,000
+33.33%
|
$15,000
$3.1 P/Share
|
|
Mar 02
2021
|
George M Lasezkay CEO |
SELL
Open market or private sale
|
Direct |
6,000
-1.36%
|
$18,000
$3.37 P/Share
|
|
Feb 10
2021
|
Clay Thorp |
SELL
Open market or private sale
|
Indirect |
32,873
-0.95%
|
$131,492
$4.43 P/Share
|
|
Jan 18
2021
|
Thomas Ciulla Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
103,125
+28.95%
|
-
|